Get the Stockscreener App
1.74
1.69%
-0.03
After Hours:
1.72
-0.02
-1.15%
Geovax Labs Inc stock is traded at $1.74, with a volume of 341.45K.
It is down -1.69% in the last 24 hours and down -34.09% over the past month.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
See More
Previous Close:
$1.77
Open:
$1.76
24h Volume:
341.45K
Relative Volume:
0.23
Market Cap:
$16.42M
Revenue:
$356.60K
Net Income/Loss:
$-24.32M
P/E Ratio:
-0.1883
EPS:
-9.24
Net Cash Flow:
$-27.24M
1W Performance:
-10.31%
1M Performance:
-34.09%
6M Performance:
-9.37%
1Y Performance:
-41.39%
1-Day Range:
$1.71
$1.7701
1-Week Range:
$1.70
$2.07
52-Week Range:
$1.0901
$11.18
Geovax Labs Inc Stock (GOVX) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678-384-7220
Address
1900 LAKE PARK DRIVE, SMYRNA
Compare GOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
1.74 | 16.42M | 356.60K | -24.32M | -27.24M | -9.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Initiated | Alliance Global Partners | Buy |
| Jul-16-24 | Initiated | ROTH MKM | Buy |
| Nov-19-20 | Initiated | Maxim Group | Buy |
Geovax Labs Inc Stock (GOVX) Latest News
Stock Surge: Geovax Labs Inc (GOVX) Closes at 1.77, Marking a -7.33 Increase/Decrease - The Dwinnex
Analysts review Geovax Labs Inc’s rating - Knox Daily
GeoVax to Present Strategic Vision for Cancer and Infectious Disease Treatments at Major Biotech Conference - Citybuzz
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Trump's Stargate Initiative: A New Era For Healthcare Innovation - Evrim Ağacı
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative - Yahoo Finance
GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
GeoVax Labs (NASDAQ:GOVXW) Shares Down 11.3% – Here’s Why - Defense World
GeoVax shareholders approve warrant exercises - MSN
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability - Yahoo Finance
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
GeoVax Labs Stockholders Approve Warrant Exercise Proposals - Defense World
GeoVax shareholders approve warrant exercises By Investing.com - Investing.com Australia
D. Boral Capital Reaffirms “Buy” Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial - Yahoo Finance
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now - GlobeNewswire Inc.
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024 - Yahoo Finance
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025 - Yahoo Finance
Contrasting GeoVax Labs (NASDAQ:GOVX) & Silverback Therapeutics (NASDAQ:SBTX) - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
GeoVax adjourns Special Meeting due to low quorum - Investing.com
GeoVax adjourns Special Meeting due to low quorum By Investing.com - Investing.com Australia
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent - The Manila Times
GeoVax Labs Secures Key Cancer Vaccine Patent, Reports Breakthrough 100% Tumor Prevention Data - StockTitan
GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78 - MSN
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Geovax Labs (FRA:E8LA) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Geovax Labs (STU:E8LA) Forward Dividend Yield % : 0.00% (As of Nov. 30, 2024) - GuruFocus.com
Alliance Global Partners Initiates Coverage of GeoVax Labs (GOVX) with Buy Recommendation - MSN
3 Penny Stocks Ready to Break Out in 2025 - sharewise
Geovax Labs (STU:E8LA) Momentum Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference - GlobeNewswire
GeoVax CEO to Present COVID-19 Vaccine & Cancer Therapy Updates at NobleCon20 | GOVX Stock News - StockTitan
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN
Q4 EPS Estimates for GeoVax Labs Lifted by Noble Financial - Defense World
GeoVax Announces Positive Interim Data Review for Phase 2 - GlobeNewswire
GeoVax regains compliance with Nasdaq listing standards By Investing.com - Investing.com Australia
GeoVax regains compliance with Nasdaq listing standards - Investing.com India
GeoVax reports progress in CLL vaccine booster trial - Investing.com India
GeoVax reports progress in CLL vaccine booster trial By Investing.com - Investing.com Canada
GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology - TipRanks
GeoVax's COVID Booster Shows Promise in Leukemia Patients, Outperforms mRNA Vaccine | GOVX Stock News - StockTitan
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - The Manila Times
Analysts Set Expectations for GeoVax Labs FY2024 Earnings - Defense World
Earnings call: GeoVax reports progress in vaccine trials, financial updates By Investing.com - Investing.com Australia
ARMISTICE CAPITAL, LLC Expands Stake in Geovax Labs Inc - GuruFocus.com
Geovax Labs Inc Stock (GOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):